BioVie Inc
bioviepharma.comWhat Do They Do?
Develops investigational medicines for neurological and neurodegenerative disorders and advanced liver disease.
10-K for FY2026, filed Aug 13, 2026BioVie Inc. (the “Company” or “we” or “our”) is a clinical-stage company developing innovative drug therapies for the treatment of…View ↗
Chronic neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including…View ↗
In liver disease, our investigational drug candidate BIV201 (continuous infusion terlipressin) was granted both FDA Fast Track status and…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2026, filed Aug 13, 2026
How Are They Changing?
Long COVID testing
The older report described plans to explore other disease uses; the latest report describes a clinical trial for neurological symptoms of Long COVID.
10-K for FY2023, filed Aug 16, 2023 10-K for FY2026, filed Aug 13, 2026Inflammation-driven insulin resistance is believed to be implicated in a broad range of serious diseases, and we plan to begin exploring…View ↗
In April 2024, the Company was awarded a clinical trial grant of $13.1 million from the U.S. Department of War (“DOW”), formerly known as…View ↗
Loading...
